High-dose midazolam infusion for refractory status epilepticus

Neurology

Volumn 82, Issue 4, 2014, Pages 359-365

  Fernandez, Andres ^a   Lantigua, Hector ^a   Lesch, Christine ^b   Shao, Belinda ^a   Foreman, Brandon ^a   Schmidt, J Michael ^a   Hirsch, Lawrence J ^a   Mayer, Stephan A ^a   Claassen, Jan ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; MIDAZOLAM;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPILEPTIC STATE; FEMALE; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; INTENSIVE CARE; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REFRACTORY STATUS EPILEPTICUS; TREATMENT OUTCOME; WITHDRAWAL SEIZURE;

ADULT; AGED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; FEMALE; HOSPITALS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; MIDDLE AGED; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84895730664     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000054     Document Type: Article

References (24)

1. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998;338:970-976.
2. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012;17:3-23.
3. Foreman B, Hirsch LJ. Epilepsy emergencies: Diagnosis and management. Neurol Clin 2012;30:11-41.
4. Bleck TP. Refractory status epilepticus. Curr Opin Crit Care 2005;11:117-120.
5. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: Still more questions than answers. Lancet Neurol 2011;10:922-930.
6. Claassen J, Hirsch LJ, Emerson RG,Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: A systematic review. Epilepsia 2002;43:146-153.
7. Rossetti AO, Milligan TA, Vulliemoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2011;14:4-10.
8. Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001;57:1036-1042.
9. Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology 2004;62:1743-1748.
10. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975;1:480-484.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-829.
12. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: Effect of treatment aggressiveness on prognosis. Arch Neurol 2005;62:1698-1702.
13. Cooper AD, Britton JW, Rabinstein AA. Functional and cognitive outcome in prolonged refractory status epilepticus. Arch Neurol 2009;66:1505-1509.
14. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: A prospective observational study. Epilepsia 2010; 51:251-256.
15. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005;76:534-539.
16. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 1992; 20:483-488.
17. Parent JM, Lowenstein DH. Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology 1994;44:1837-1840.
18. Naritoku DK, Sinha S. Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology 2000;54:1366-1368.
19. Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001;42:380-386.
20. Ulvi H, Yoldas T, Mungen B, Yigiter R. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. Neurol Sci 2002;23:177-182.
21. Bodmer M, Link B, Grignaschi N, et al. Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. Ther Drug Monit 2008;30:120-124.
22. Morrison G, Gibbons E, Whitehouse WP. High-dose midazolam therapy for refractory status epilepticus in children. Intensive Care Med 2006;32:2070-2076.
23. Claassen J, Silbergleit R, Weingart SD, Smith WS. Emergency neurological life support: Status epilepticus. Neurocrit Care 2012;17(suppl 1):S73-S78.
24. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: Frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59:205-210.